Hide metadata

dc.contributor.authorKarabeg, Mia
dc.contributor.authorPetrovski, Goran
dc.contributor.authorHertzberg, Silvia N.
dc.contributor.authorErke, Maja G.
dc.contributor.authorFosmark, Dag S.
dc.contributor.authorRussell, Greg
dc.contributor.authorMoe, Morten C.
dc.contributor.authorVolke, Vallo
dc.contributor.authorRaudonis, Vidas
dc.contributor.authorVerkauskiene, Rasa
dc.contributor.authorSokolovska, Jelizaveta
dc.contributor.authorHaugen, Inga-Britt K.
dc.contributor.authorPetrovski, Beata E.
dc.date.accessioned2024-05-28T05:05:54Z
dc.date.available2024-05-28T05:05:54Z
dc.date.issued2024
dc.identifier.citationInternational Journal of Retina and Vitreous. 2024 May 23;10(1):40
dc.identifier.urihttp://hdl.handle.net/10852/111017
dc.description.abstractBackground Diabetic retinopathy (DR) is the leading cause of adult blindness in the working age population worldwide, which can be prevented by early detection. Regular eye examinations are recommended and crucial for detecting sight-threatening DR. Use of artificial intelligence (AI) to lessen the burden on the healthcare system is needed. Purpose To perform a pilot cost-analysis study for detecting DR in a cohort of minority women with DM in Oslo, Norway, that have the highest prevalence of diabetes mellitus (DM) in the country, using both manual (ophthalmologist) and autonomous (AI) grading. This is the first study in Norway, as far as we know, that uses AI in DR- grading of retinal images. Methods On Minority Women’s Day, November 1, 2017, in Oslo, Norway, 33 patients (66 eyes) over 18 years of age diagnosed with DM (T1D and T2D) were screened. The Eidon - True Color Confocal Scanner (CenterVue, United States) was used for retinal imaging and graded for DR after screening had been completed, by an ophthalmologist and automatically, using EyeArt Automated DR Detection System, version 2.1.0 (EyeArt, EyeNuk, CA, USA). The gradings were based on the International Clinical Diabetic Retinopathy (ICDR) severity scale [1] detecting the presence or absence of referable DR. Cost-minimization analyses were performed for both grading methods. Results 33 women (64 eyes) were eligible for the analysis. A very good inter-rater agreement was found: 0.98 (P < 0.01), between the human and AI-based EyeArt grading system for detecting DR. The prevalence of DR was 18.6% (95% CI: 11.4–25.8%), and the sensitivity and specificity were 100% (95% CI: 100–100% and 95% CI: 100–100%), respectively. The cost difference for AI screening compared to human screening was $143 lower per patient (cost-saving) in favour of AI. Conclusion Our results indicate that The EyeArt AI system is both a reliable, cost-saving, and useful tool for DR grading in clinical practice.
dc.language.isoeng
dc.rightsThe Author(s); licensee BioMed Central Ltd.
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleA pilot cost-analysis study comparing AI-based EyeArt® and ophthalmologist assessment of diabetic retinopathy in minority women in Oslo, Norway
dc.typeJournal article
dc.date.updated2024-05-28T05:05:55Z
dc.creator.authorKarabeg, Mia
dc.creator.authorPetrovski, Goran
dc.creator.authorHertzberg, Silvia N.
dc.creator.authorErke, Maja G.
dc.creator.authorFosmark, Dag S.
dc.creator.authorRussell, Greg
dc.creator.authorMoe, Morten C.
dc.creator.authorVolke, Vallo
dc.creator.authorRaudonis, Vidas
dc.creator.authorVerkauskiene, Rasa
dc.creator.authorSokolovska, Jelizaveta
dc.creator.authorHaugen, Inga-Britt K.
dc.creator.authorPetrovski, Beata E.
dc.identifier.doihttps://doi.org/10.1186/s40942-024-00547-3
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.type.versionPublishedVersion
cristin.articleid40


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International